New Report on US Solid Tumor Testing Industry 2018 at Market Research Nest

MarketResearchNest.com adds “Solid Tumor Testing Market in the US 2018-2022” new report to its research database. The report spread across 109 pages with table and figures in it.

 

About Solid Tumor Testing

Solid tumor testing is a medical procedure that helps in the early detection of cancer. It is done to avoid the spread of cancerous cells throughout the body and allow for effective treatment.

 

Research analysts forecast the solid tumor testing market in the US to grow at a CAGR of 10.72% during the period 2018-2022.

 

Covered in this report

The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

 

Browse full table of contents and data tables at https://www.marketresearchnest.com/Solid-Tumor-Testing-Market-in-the-US-2018-2022.html

 

Research report, Solid Tumor Testing Market in the US 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

 

Research recognizes the following companies as the key players in the solid tumor testing market in the US: Agilent Technologies, Becton, Dickinson and Company, Danaher, F. Hoffmann-La Roche, Illumina, and Thermo Fisher Scientific.

 

Commenting on the report, an analyst from Research team said: “One trend in the market is adoption of NGS in cancer diagnostics. The growing adoption of NGS in cancer diagnostics is identified to be one of the key trends driving the growth of the solid tumor testing market in the US. Next-generation sequencing (NGS) is a high-throughput methodology that enables rapid sequencing of the base pairs in DNA or RNA samples.

 

Order a Purchase Report Copy at https://www.marketresearchnest.com/report/purchase/347740

 

According to the report, one driver in the market is growing prevalence of cancer. Globally, cancer is the primary cause for the high mortality rates among all age groups. In 2014, 1.6 million new cancer cases were diagnosed out of which 600,000 individuals succumbed to the disease. Many types of cancer are curable if diagnosed at early stage, however, few are fatal.

 

Further, the report states that one challenge in the market is high cost of sequencing. As sequencing involves the handling of high throughput data, the maintenance of precision and accuracy requires highly skilled personnel and cutting-edge technology and equipment. Thus, setting up a laboratory consumes a significant amount of capital.

 

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

 

Key questions answered in this report

 

– What will the market size be in 2022 and what will the growth rate be?

– What are the key market trends?

– What is driving this market?

– What are the challenges to market growth?

– Who are the key vendors in this market space?

 

Enquiry before Buying at https://www.marketresearchnest.com/report/enquirybuy/347740

 

About: 

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on industries, organizations, products, and trends.

 

Contact

Mr. Jeet Jain

Sales Manager

sales@marketresearchnest.com

+1-240-284-8070(U.S)

+44-20-3290-4151(U.K)

Connect with us:  Google+ | LinkedIn | Twitter | Facebook

About pr1@letsbrandconsultancy.com

View all posts by pr1@letsbrandconsultancy.com →